市場調査レポート

商品コード

1744544

CT/NG検査市場の2032年までの予測：製品別、検査タイプ別、エンドユーザー別、地域別の世界分析

CT/NG Testing Market Forecasts to 2032 - Global Analysis By Product (Assays & Kits and Instruments/Analyzers), Testing Type (Laboratory Testing and Point-of-care (POC) Testing), End User and By Geography

出版日: 2025年06月06日
発行: Stratistics Market Research Consulting
ページ情報: 英文 200+ Pages
納期: 2～3営業日

カスタマイズ可能

価格

PDF (Single User License)

USD 4,150 597,932円

レポートPDFを1名様のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は1回のみ可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (2-5 User License)

USD 5,250 756,420円

レポートPDFを同一事業所（所在地）内の5名までご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は5回まで可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF & Excel (Site License)

USD 6,350 914,908円

レポートPDFおよびExcelを同一事業所（所在地）内のすべての方にご利用頂けるライセンスです。PDFおよびExcel内のテキスト等のコピーは可能です。PDFおよびExcelの印刷は5回まで可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

PDF & Excel (Global Site License)

USD 7,500 1,080,600円

レポートPDFおよびExcelを企業内すべての方に使用頂けるライセンスです。PDFおよびExcel内のテキスト等のコピーは可能です。PDFおよびExcelの印刷は10回まで可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=144.08円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

Stratistics MRCによると、CT/NG検査の世界市場は2025年に21億6,000万米ドルを占め、予測期間中のCAGRは10.6％で成長し、2032年には43億8,000万米ドルに達すると予測されています。

CT/NG検査とは、世界で最も一般的な性感染症（STI）であるクラミジア・トラコマティス（CT）と淋菌（NG）を検出するための診断検査を指します。この2つの感染症は自覚症状がないことが多いもの、治療を受けなければ骨盤内炎症性疾患や不妊症などの大きな健康問題を引き起こす可能性があるため、これらの検査は早期診断と治療に不可欠です。通常、CT/NG検査には核酸増幅検査（NAAT）が使用され、尿検体、膣スワブ、その他の検体を用いて実施することができ、高い感度と特異度を有しています。定期的なスクリーニングは、特に性的に活発な人々の間で、これらの感染症の蔓延を阻止するための重要な公衆衛生戦術です。

米国疾病予防管理センター（CDC）によると、2023年には米国で240万件を超えるクラミジア、淋病、梅毒の症例が報告されました。クラミジアは160万件以上を占め、最も多く報告されている性感染症（STI）です。

STI有病率の増加

CT/NG検査市場を推進する主な要因の1つは、クラミジアと淋病の世界の罹患率の上昇です。CDCによると、米国では2021年だけで70万件以上の淋菌感染と160万件以上のクラミジア感染が報告されています。無症候性感染は診断されないことが多いため、これらの数字はおそらく過小評価であろう。世界保健機関（WHO）によると、クラミジアと淋病は、世界中で毎年新たに発生する治癒可能なSTI感染症3億7,400万件のかなりの部分を占めています。病気のさらなる蔓延を食い止め、できるだけ早く治療を開始するために、この高い疾病負担の結果、診断検査は劇的に増加しています。

高価な高度診断検査

核酸増幅検査（NAAT）のような高度な診断技術は、その感度と特異度が高いにもかかわらず、コストが高いため、特に低・中所得国ではアクセスが制限される可能性があります。資金不足の公衆衛生システムや小規模の診療所では、これらの検査に必要な高価な試薬、特殊な機器、熟練した人材を確保できない場合があります。特にSTI検査の資金が乏しい地域では、このような経済的な障害が普及を妨げています。さらに、特に保険に加入していない人々や公的ヘルスケア制度のない地域では、自己負担額が定期的に検査を受ける意欲を失わせることもあります。

遠隔医療とデジタルヘルスの統合

遠隔医療プラットフォームとデジタルヘルス・ソリューションの利用拡大により、CT/NG検査に新たな道が開かれつつあります。人々は、自宅での検査キットやアプリベースの診察により、簡単かつ慎重にSTIサービスにアクセスすることができます。これらのプラットフォームは、治療のための電子処方、結果の遠隔配信、サンプル採取の指示をサポートすることができます。より良いデータ収集と接触者追跡もデジタルヘルスツールによって可能になり、公衆衛生サーベイランスをサポートします。さらに、COVID-19の大流行がこの動向を加速させ、患者と医療提供者の双方がバーチャルケアをより安心して利用できるようになっていることを実証しているように、診断企業は検査をデジタルサポートサービスとバンドルする長期的な機会を有しています。

低資源環境におけるシンドロミック管理との競合

資金不足と検査機関へのアクセス不足のため、STIのシンドロミック管理は多くの発展途上国でまだ広く用いられています。この方法は、精度は低いもの、確定検査を必要とせずに症状を治療することで、診断の必要性を減らすものです。症候学的管理の継続的な使用は、特に費用が重要視される公衆衛生システムにおいて、CT/NG検査の拡大能力を危うくします。さらに、診断が最も必要とされる高負担国においては、ポイントオブケア検査がより利用しやすくなり、現行の手順に組み込まれない限り、診断の導入は制限されたままとなる可能性があります。

COVID-19の影響：

COVID-19パンデミックはCT/NG検査市場にさまざまな影響を与えました。当初は、サプライチェーンの混乱、ヘルスケアシステムへの過重な負担、検査リソースのSARS-CoV-2診断への再配分により、検査サービスが中断されました。多くの地域で、淋病やクラミジアなどのSTIの定期検診プログラムが中止または縮小された結果、検査数は一時的に減少し、診断も遅れました。しかし、このパンデミックは、ポイントオブケア診断、遠隔医療、自己採取キットの普及を早め、よりアクセスしやすく分散化されたSTI検査の基盤を確立しました。

アッセイ＆キット分野は予測期間中最大となる見込み

アッセイ＆キット分野は、予測期間中に最大の市場シェアを占めると予想されます。核酸増幅検査（NAAT）のような、CT/NG感染の特定に非常に高感度かつ特異的な分子診断検査が広く使用されていることが、この優位性の原因となっています。これらのアッセイは、使用が簡便で、納期が早く、自動化プラットフォームに適合しているため、臨床検査室、病院、さらには家庭用検査キットでも頻繁に利用されています。さらに、アッセイベースのソリューションは、特に無症候性患者における早期かつ正確な診断の必要性の高まりにより、ますます普及しています。その結果、この市場セグメントは現在、市場収益の最大部分を占めています。

予測期間中にCAGRが最も高くなると予想されるのは在宅ケア分野

予測期間中、最も高い成長率を示すと予測されるのは、在宅ケア設定分野です。この成長の主な原動力は、アクセスしやすく、便利で、プライベートなSTIスクリーニングに対する需要の高まりです。遠隔医療ベースの診断サービスや自宅でのサンプル採取キットは、特にCOVID-19の大流行以来、患者の嗜好が変わって以来、ますます人気が高まっています。医療機関を訪れることなく、認定ラボへのサンプル送付や自己検査を可能にすることで、これらのソリューションは検査頻度を向上させ、スティグマを軽減します。さらに、自己検査の使いやすさ、意識の高まり、技術開発は、この市場の成長を大きく加速させると予想されます。

最大のシェアを占める地域：

予測期間中、アジア太平洋が最大の市場シェアを占めると予想されるが、これは主に同地域の人口規模、STI感染率の上昇、性的健康意識の高まりによるものです。さらに、同地域の市場支配は、中国、インド、日本、オーストラリアなどの国々で高度な診断技術へのアクセスが拡大していること、医療インフラの拡大、STIスクリーニングプログラムを支援する政府のイニシアチブによるところが大きいです。アジア太平洋の市場は、ポイントオブケア検査キットや核酸増幅検査（NAAT）の使用の増加により拡大しており、この地域はCT/NG検査において世界で最も著名な場所となっています。

CAGRが最も高い地域：

予測期間中、北米地域は最も高いCAGRを示すと予測されます。これは、強固なヘルスケアシステム、性病に関する高い知識、最先端の診断ツールの広範な使用によるものです。強力な償還慣行、検診イニシアチブの拡大、継続的な研究開発努力が市場の拡大に寄与しています。さらに、北米におけるCT/NG検査市場の力強い成長を支える変数として、高感度かつ迅速な検査技術の利用可能性、性的健康プログラムに対する公共・民間投資の増加などが挙げられます。

無料のカスタマイズサービス

本レポートをご購読のお客様には、以下の無料カスタマイズオプションのいずれかをご利用いただけます：

企業プロファイル
- 追加市場企業の包括的プロファイリング（3社まで）
- 主要企業のSWOT分析（3社まで）
地域セグメンテーション
- 顧客の関心に応じた主要国の市場推計・予測・CAGR（注：フィージビリティチェックによる）
競合ベンチマーキング
- 製品ポートフォリオ、地理的プレゼンス、戦略的提携に基づく主要企業のベンチマーキング

北米
- 米国
- カナダ
- メキシコ
欧州
- ドイツ
- 英国
- イタリア
- フランス
- スペイン
- その他の欧州
アジア太平洋
- 日本
- 中国
- インド
- オーストラリア
- ニュージーランド
- 韓国
- その他のアジア太平洋
南米
- アルゼンチン
- ブラジル
- チリ
- その他の南米
中東・アフリカ
- サウジアラビア
- アラブ首長国連邦
- カタール
- 南アフリカ
- その他の中東・アフリカ

第9章主な発展

契約、パートナーシップ、コラボレーション、ジョイントベンチャー
買収と合併
新製品発売
事業拡大
その他の主要戦略

第10章企業プロファイリング

Bio-Rad Laboratories, Inc.
F. Hoffmann-La Roche Ltd.
Thermo Fisher Scientific, Inc.
Binx Health, Inc.
Abbott Laboratories
Hologic Inc.
Siemens Healthineers AG
ELITech Group SAS
Danaher Corporation
Seegene, Inc.
Genetic Signatures Ltd.
Becton, Dickinson and Company（BD）
Qiagen N.V.
Meridian Bioscience Inc.
PerkinElmer Inc.

図表

List of Tables

Table 1 Global CT/NG Testing Market Outlook, By Region (2024-2032) ($MN)
Table 2 Global CT/NG Testing Market Outlook, By Product (2024-2032) ($MN)
Table 3 Global CT/NG Testing Market Outlook, By Assays & Kits (2024-2032) ($MN)
Table 4 Global CT/NG Testing Market Outlook, By Instruments/Analyzers (2024-2032) ($MN)
Table 5 Global CT/NG Testing Market Outlook, By Testing Type (2024-2032) ($MN)
Table 6 Global CT/NG Testing Market Outlook, By Laboratory Testing (2024-2032) ($MN)
Table 7 Global CT/NG Testing Market Outlook, By Nucleic Acid Amplification Tests (NAAT) (2024-2032) ($MN)
Table 8 Global CT/NG Testing Market Outlook, By Immunoassays (2024-2032) ($MN)
Table 9 Global CT/NG Testing Market Outlook, By Culture Tests (2024-2032) ($MN)
Table 10 Global CT/NG Testing Market Outlook, By Point-of-care (POC) Testing (2024-2032) ($MN)
Table 11 Global CT/NG Testing Market Outlook, By Rapid Diagnostic Tests (RDT) (2024-2032) ($MN)
Table 12 Global CT/NG Testing Market Outlook, By Self-Testing Kits (2024-2032) ($MN)
Table 13 Global CT/NG Testing Market Outlook, By End User (2024-2032) ($MN)
Table 14 Global CT/NG Testing Market Outlook, By Diagnostic Laboratories (2024-2032) ($MN)
Table 15 Global CT/NG Testing Market Outlook, By Hospitals & Clinics (2024-2032) ($MN)
Table 16 Global CT/NG Testing Market Outlook, By Home Care Settings (2024-2032) ($MN)
Table 17 Global CT/NG Testing Market Outlook, By Other End Users (2024-2032) ($MN)
Table 18 North America CT/NG Testing Market Outlook, By Country (2024-2032) ($MN)
Table 19 North America CT/NG Testing Market Outlook, By Product (2024-2032) ($MN)
Table 20 North America CT/NG Testing Market Outlook, By Assays & Kits (2024-2032) ($MN)
Table 21 North America CT/NG Testing Market Outlook, By Instruments/Analyzers (2024-2032) ($MN)
Table 22 North America CT/NG Testing Market Outlook, By Testing Type (2024-2032) ($MN)
Table 23 North America CT/NG Testing Market Outlook, By Laboratory Testing (2024-2032) ($MN)
Table 24 North America CT/NG Testing Market Outlook, By Nucleic Acid Amplification Tests (NAAT) (2024-2032) ($MN)
Table 25 North America CT/NG Testing Market Outlook, By Immunoassays (2024-2032) ($MN)
Table 26 North America CT/NG Testing Market Outlook, By Culture Tests (2024-2032) ($MN)
Table 27 North America CT/NG Testing Market Outlook, By Point-of-care (POC) Testing (2024-2032) ($MN)
Table 28 North America CT/NG Testing Market Outlook, By Rapid Diagnostic Tests (RDT) (2024-2032) ($MN)
Table 29 North America CT/NG Testing Market Outlook, By Self-Testing Kits (2024-2032) ($MN)
Table 30 North America CT/NG Testing Market Outlook, By End User (2024-2032) ($MN)
Table 31 North America CT/NG Testing Market Outlook, By Diagnostic Laboratories (2024-2032) ($MN)
Table 32 North America CT/NG Testing Market Outlook, By Hospitals & Clinics (2024-2032) ($MN)
Table 33 North America CT/NG Testing Market Outlook, By Home Care Settings (2024-2032) ($MN)
Table 34 North America CT/NG Testing Market Outlook, By Other End Users (2024-2032) ($MN)
Table 35 Europe CT/NG Testing Market Outlook, By Country (2024-2032) ($MN)
Table 36 Europe CT/NG Testing Market Outlook, By Product (2024-2032) ($MN)
Table 37 Europe CT/NG Testing Market Outlook, By Assays & Kits (2024-2032) ($MN)
Table 38 Europe CT/NG Testing Market Outlook, By Instruments/Analyzers (2024-2032) ($MN)
Table 39 Europe CT/NG Testing Market Outlook, By Testing Type (2024-2032) ($MN)
Table 40 Europe CT/NG Testing Market Outlook, By Laboratory Testing (2024-2032) ($MN)
Table 41 Europe CT/NG Testing Market Outlook, By Nucleic Acid Amplification Tests (NAAT) (2024-2032) ($MN)
Table 42 Europe CT/NG Testing Market Outlook, By Immunoassays (2024-2032) ($MN)
Table 43 Europe CT/NG Testing Market Outlook, By Culture Tests (2024-2032) ($MN)
Table 44 Europe CT/NG Testing Market Outlook, By Point-of-care (POC) Testing (2024-2032) ($MN)
Table 45 Europe CT/NG Testing Market Outlook, By Rapid Diagnostic Tests (RDT) (2024-2032) ($MN)
Table 46 Europe CT/NG Testing Market Outlook, By Self-Testing Kits (2024-2032) ($MN)
Table 47 Europe CT/NG Testing Market Outlook, By End User (2024-2032) ($MN)
Table 48 Europe CT/NG Testing Market Outlook, By Diagnostic Laboratories (2024-2032) ($MN)
Table 49 Europe CT/NG Testing Market Outlook, By Hospitals & Clinics (2024-2032) ($MN)
Table 50 Europe CT/NG Testing Market Outlook, By Home Care Settings (2024-2032) ($MN)
Table 51 Europe CT/NG Testing Market Outlook, By Other End Users (2024-2032) ($MN)
Table 52 Asia Pacific CT/NG Testing Market Outlook, By Country (2024-2032) ($MN)
Table 53 Asia Pacific CT/NG Testing Market Outlook, By Product (2024-2032) ($MN)
Table 54 Asia Pacific CT/NG Testing Market Outlook, By Assays & Kits (2024-2032) ($MN)
Table 55 Asia Pacific CT/NG Testing Market Outlook, By Instruments/Analyzers (2024-2032) ($MN)
Table 56 Asia Pacific CT/NG Testing Market Outlook, By Testing Type (2024-2032) ($MN)
Table 57 Asia Pacific CT/NG Testing Market Outlook, By Laboratory Testing (2024-2032) ($MN)
Table 58 Asia Pacific CT/NG Testing Market Outlook, By Nucleic Acid Amplification Tests (NAAT) (2024-2032) ($MN)
Table 59 Asia Pacific CT/NG Testing Market Outlook, By Immunoassays (2024-2032) ($MN)
Table 60 Asia Pacific CT/NG Testing Market Outlook, By Culture Tests (2024-2032) ($MN)
Table 61 Asia Pacific CT/NG Testing Market Outlook, By Point-of-care (POC) Testing (2024-2032) ($MN)
Table 62 Asia Pacific CT/NG Testing Market Outlook, By Rapid Diagnostic Tests (RDT) (2024-2032) ($MN)
Table 63 Asia Pacific CT/NG Testing Market Outlook, By Self-Testing Kits (2024-2032) ($MN)
Table 64 Asia Pacific CT/NG Testing Market Outlook, By End User (2024-2032) ($MN)
Table 65 Asia Pacific CT/NG Testing Market Outlook, By Diagnostic Laboratories (2024-2032) ($MN)
Table 66 Asia Pacific CT/NG Testing Market Outlook, By Hospitals & Clinics (2024-2032) ($MN)
Table 67 Asia Pacific CT/NG Testing Market Outlook, By Home Care Settings (2024-2032) ($MN)
Table 68 Asia Pacific CT/NG Testing Market Outlook, By Other End Users (2024-2032) ($MN)
Table 69 South America CT/NG Testing Market Outlook, By Country (2024-2032) ($MN)
Table 70 South America CT/NG Testing Market Outlook, By Product (2024-2032) ($MN)
Table 71 South America CT/NG Testing Market Outlook, By Assays & Kits (2024-2032) ($MN)
Table 72 South America CT/NG Testing Market Outlook, By Instruments/Analyzers (2024-2032) ($MN)
Table 73 South America CT/NG Testing Market Outlook, By Testing Type (2024-2032) ($MN)
Table 74 South America CT/NG Testing Market Outlook, By Laboratory Testing (2024-2032) ($MN)
Table 75 South America CT/NG Testing Market Outlook, By Nucleic Acid Amplification Tests (NAAT) (2024-2032) ($MN)
Table 76 South America CT/NG Testing Market Outlook, By Immunoassays (2024-2032) ($MN)
Table 77 South America CT/NG Testing Market Outlook, By Culture Tests (2024-2032) ($MN)
Table 78 South America CT/NG Testing Market Outlook, By Point-of-care (POC) Testing (2024-2032) ($MN)
Table 79 South America CT/NG Testing Market Outlook, By Rapid Diagnostic Tests (RDT) (2024-2032) ($MN)
Table 80 South America CT/NG Testing Market Outlook, By Self-Testing Kits (2024-2032) ($MN)
Table 81 South America CT/NG Testing Market Outlook, By End User (2024-2032) ($MN)
Table 82 South America CT/NG Testing Market Outlook, By Diagnostic Laboratories (2024-2032) ($MN)
Table 83 South America CT/NG Testing Market Outlook, By Hospitals & Clinics (2024-2032) ($MN)
Table 84 South America CT/NG Testing Market Outlook, By Home Care Settings (2024-2032) ($MN)
Table 85 South America CT/NG Testing Market Outlook, By Other End Users (2024-2032) ($MN)
Table 86 Middle East & Africa CT/NG Testing Market Outlook, By Country (2024-2032) ($MN)
Table 87 Middle East & Africa CT/NG Testing Market Outlook, By Product (2024-2032) ($MN)
Table 88 Middle East & Africa CT/NG Testing Market Outlook, By Assays & Kits (2024-2032) ($MN)
Table 89 Middle East & Africa CT/NG Testing Market Outlook, By Instruments/Analyzers (2024-2032) ($MN)
Table 90 Middle East & Africa CT/NG Testing Market Outlook, By Testing Type (2024-2032) ($MN)
Table 91 Middle East & Africa CT/NG Testing Market Outlook, By Laboratory Testing (2024-2032) ($MN)
Table 92 Middle East & Africa CT/NG Testing Market Outlook, By Nucleic Acid Amplification Tests (NAAT) (2024-2032) ($MN)
Table 93 Middle East & Africa CT/NG Testing Market Outlook, By Immunoassays (2024-2032) ($MN)
Table 94 Middle East & Africa CT/NG Testing Market Outlook, By Culture Tests (2024-2032) ($MN)
Table 95 Middle East & Africa CT/NG Testing Market Outlook, By Point-of-care (POC) Testing (2024-2032) ($MN)
Table 96 Middle East & Africa CT/NG Testing Market Outlook, By Rapid Diagnostic Tests (RDT) (2024-2032) ($MN)
Table 97 Middle East & Africa CT/NG Testing Market Outlook, By Self-Testing Kits (2024-2032) ($MN)
Table 98 Middle East & Africa CT/NG Testing Market Outlook, By End User (2024-2032) ($MN)
Table 99 Middle East & Africa CT/NG Testing Market Outlook, By Diagnostic Laboratories (2024-2032) ($MN)
Table 100 Middle East & Africa CT/NG Testing Market Outlook, By Hospitals & Clinics (2024-2032) ($MN)
Table 101 Middle East & Africa CT/NG Testing Market Outlook, By Home Care Settings (2024-2032) ($MN)
Table 102 Middle East & Africa CT/NG Testing Market Outlook, By Other End Users (2024-2032) ($MN)

Product Code: SMRC29592

According to Stratistics MRC, the Global CT/NG Testing Market is accounted for $2.16 billion in 2025 and is expected to reach $4.38 billion by 2032 growing at a CAGR of 10.6% during the forecast period. CT/NG testing refers to diagnostic tests used to detect Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG), two of the most common sexually transmitted infections (STIs) worldwide. These tests are essential for early diagnosis and treatment because, although both infections frequently show no symptoms, if treatment is not received, they can cause major health problems like pelvic inflammatory disease and infertility. Typically, CT/NG testing uses nucleic acid amplification tests (NAATs), which can be carried out with urine samples, vaginal swabs, or other specimen types and have high sensitivity and specificity. Regular screening is a crucial public health tactic to stop the spread of these infections, particularly among sexually active people.

According to the Centers for Disease Control and Prevention (CDC), over 2.4 million cases of chlamydia, gonorrhea, and syphilis were reported in the United States in 2023. Chlamydia accounted for more than 1.6 million cases, making it the most commonly reported sexually transmitted infection (STI).

Market Dynamics:

Driver:

Growing STI prevalence

One of the major factors propelling the CT/NG testing market is the rising global incidence of chlamydia and gonorrhea. Over 700,000 cases of gonorrhea and over 1.6 million cases of chlamydia were reported in the United States in 2021 alone, according to the CDC. Because asymptomatic infections often go undiagnosed, these figures are probably underestimates. According to the World Health Organization (WHO), Chlamydia and gonorrhea account for a significant portion of the 374 million new curable STI infections that occur worldwide each year. In order to stop the disease from spreading further and to start treatment as soon as possible, diagnostic testing has increased dramatically as a result of this high disease burden.

Restraint:

Expensive advanced diagnostic testing

The high cost of advanced diagnostic technologies, like nucleic acid amplification tests (NAATs), can restrict access, particularly in low- and middle-income nations, despite their high sensitivity and specificity. Underfunded public health systems or smaller clinics may not be able to afford the costly reagents, specialized equipment, and skilled personnel needed for these tests. Widespread adoption is hampered by this financial obstacle, especially in places where STI testing funding is scarce. Moreover, the out-of-pocket expenses can also discourage people from getting tested on a regular basis, especially for populations without insurance or in areas without public healthcare systems.

Opportunity:

Integration of telemedicine and digital health

The increasing use of telemedicine platforms and digital health solutions is opening up new avenues for CT/NG testing. People can easily and discreetly access STI services with at-home testing kits and app-based consultations. These platforms can support electronic prescriptions for treatment, remote result delivery, and instructions for sample collection. Better data collection and contact tracing are also made possible by digital health tools, which support public health surveillance. Additionally, diagnostic companies have a long-term opportunity to bundle testing with digital support services, as the COVID-19 pandemic has accelerated this trend and demonstrated that both patients and providers are growing more at ease with virtual care.

Threat:

Competition in low-resource environments from syndromic management

Due to a lack of funding and access to laboratory testing, syndromic management of STIs is still widely used in many developing nations. This method reduces the need for diagnostics by treating symptoms without the need for confirmatory testing, despite being less accurate. The continued use of syndromic management jeopardizes CT/NG testing's ability to expand, particularly in public health systems where cost is a key consideration. Furthermore, diagnostic adoption may remain restricted in high-burden nations where it is most needed unless point-of-care tests become more accessible and incorporated into current procedures.

Covid-19 Impact:

The COVID-19 pandemic had a mixed effect on the CT/NG testing market. At first, it caused testing services to be disrupted because of supply chain disruptions, the overburden on the healthcare system, and the reallocation of laboratory resources to SARS-CoV-2 diagnostics. As a result of the suspension or reduction of routine screening programs for STIs, such as gonorrhea and chlamydia, in many areas, testing volumes temporarily decreased and diagnoses were delayed. The pandemic did, however, also hasten the uptake of point-of-care diagnostics, telemedicine, and self-collection kits, establishing the foundation for more accessible and decentralized STI testing.

The assays & kits segment is expected to be the largest during the forecast period

The assays & kits segment is expected to account for the largest market share during the forecast period. The extensive use of molecular diagnostic tests, like nucleic acid amplification tests (NAATs), which are very sensitive and specific for identifying CT/NG infections, is what is causing this dominance. Because of their simplicity of use, quick turnaround times, and compatibility with automated platforms, these assays are frequently utilized in clinical laboratories, hospitals, and even at-home testing kits. Moreover, assay-based solutions have become increasingly popular due to the increasing need for early and precise diagnosis, particularly in asymptomatic individuals. As a result, this market segment now accounts for the largest portion of market revenue.

The home care settings segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the home care settings segment is predicted to witness the highest growth rate. The primary drivers of this growth are the growing demands for STI screening that are accessible, convenient, and private. Telehealth-based diagnostic services and at-home sample collection kits have become increasingly popular, especially since the COVID-19 pandemic changed patient preferences. By enabling people to send samples to accredited labs and perform self-tests without having to visit medical facilities, these solutions improve testing frequency and lessen stigma. Additionally, self-testing's ease of use, growing awareness, and technological developments are anticipated to greatly speed up this market's growth.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share, mainly due to the region's population size, rising STI rates, and growing sexual health consciousness. Furthermore, the region's market dominance is largely due to growing access to advanced diagnostic technologies in nations like China, India, Japan, and Australia, as well as expanding healthcare infrastructure and government initiatives supporting STI screening programs. The market in Asia-Pacific is expanding due to the growing use of point-of-care testing kits and nucleic acid amplification tests (NAATs), which has made the region the world's most prominent location for CT/NG testing.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, motivated by a robust healthcare system, a high level of knowledge about STDs, and the broad use of cutting-edge diagnostic tools. Strong reimbursement practices, expanding screening initiatives and continuous R&D efforts all contribute to the market's expansion. Additionally, variables supporting the strong growth of the CT/NG testing market in North America include the availability of highly sensitive and quick testing techniques, as well as rising public and private investments in sexual health programs.

Key players in the market

Some of the key players in CT/NG Testing Market include Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific, Inc., Binx Health, Inc., Abbott Laboratories, Hologic Inc., Siemens Healthineers AG, ELITech Group SAS, Danaher Corporation, Seegene, Inc., Genetic Signatures Ltd., Becton, Dickinson and Company (BD), Qiagen N.V., Meridian Bioscience Inc. and PerkinElmer Inc.

Key Developments:

In February 2025, Bio-Rad Laboratories, Inc launched its TrailBlazer Tag and TrailBlazer StarBright Dye Label Kits. The new kits are designed to offer a convenient method to label any antibody with one of Bio-Rad's StarBright Dyes, for use in either flow cytometry or fluorescent western blot experiments. The new two-kit system provides researchers access to Bio-Rad's StarBright Blue and StarBright Violet Dyes, employing Bio-Rad's SpyTag and SpyCatcher technology to conjugate a dye to an antibody of choice.

In February 2025, Thermo Fisher Scientific Inc. announced that the company has entered into a definitive agreement with Solventum to acquire Solventum's Purification & Filtration business for approximately $4.1 billion in cash. Solventum's Purification & Filtration business is a leading provider of purification and filtration technologies used in the production of biologics as well as in medical technologies and industrial applications.

In November 2024, Roche announced that it has entered into a definitive merger agreement to acquire Poseida Therapeutics, Inc, a public clinical-stage biopharmaceutical company pioneering donor-derived CAR-T cell therapies. Based in San Diego, California, Poseida's R&D portfolio includes pre-clinical and clinical-stage off-the-shelf CAR-T therapies across several therapeutic areas including haematological malignancies, solid tumours, and autoimmune disease, as well as manufacturing capabilities and technology platforms.

Products Covered:

Assays & Kits
Instruments/Analyzers

Testing Types Covered:

Laboratory Testing
Point-of-care (POC) Testing

End Users Covered:

Diagnostic Laboratories
Hospitals & Clinics
Home Care Settings
Other End Users

Regions Covered:

North America
- US
- Canada
- Mexico
Europe
- Germany
- UK
- Italy
- France
- Spain
- Rest of Europe
Asia Pacific
- Japan
- China
- India
- Australia
- New Zealand
- South Korea
- Rest of Asia Pacific
South America
- Argentina
- Brazil
- Chile
- Rest of South America
Middle East & Africa
- Saudi Arabia
- UAE
- Qatar
- South Africa
- Rest of Middle East & Africa

What our report offers:

Market share assessments for the regional and country-level segments
Strategic recommendations for the new entrants
Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
Strategic recommendations in key business segments based on the market estimations
Competitive landscaping mapping the key common trends
Company profiling with detailed strategies, financials, and recent developments
Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

Company Profiling
- Comprehensive profiling of additional market players (up to 3)
- SWOT Analysis of key players (up to 3)
Regional Segmentation
- Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
Competitive Benchmarking
- Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

1 Executive Summary

2 Preface

2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
- 2.4.1 Data Mining
- 2.4.2 Data Analysis
- 2.4.3 Data Validation
- 2.4.4 Research Approach
2.5 Research Sources
- 2.5.1 Primary Research Sources
- 2.5.2 Secondary Research Sources
- 2.5.3 Assumptions

3 Market Trend Analysis

3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Product Analysis
3.7 End User Analysis
3.8 Emerging Markets
3.9 Impact of Covid-19

4 Porters Five Force Analysis

4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 Global CT/NG Testing Market, By Product

5.1 Introduction
5.2 Assays & Kits
5.3 Instruments/Analyzers

6 Global CT/NG Testing Market, By Testing Type

6.1 Introduction
6.2 Laboratory Testing
- 6.2.1 Nucleic Acid Amplification Tests (NAAT)
- 6.2.2 Immunoassays
- 6.2.3 Culture Tests
6.3 Point-of-care (POC) Testing
- 6.3.1 Rapid Diagnostic Tests (RDT)
- 6.3.2 Self-Testing Kits

7 Global CT/NG Testing Market, By End User

7.1 Introduction
7.2 Diagnostic Laboratories
7.3 Hospitals & Clinics
7.4 Home Care Settings
7.5 Other End Users

8 Global CT/NG Testing Market, By Geography

8.1 Introduction
8.2 North America
- 8.2.1 US
- 8.2.2 Canada
- 8.2.3 Mexico
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 Italy
- 8.3.4 France
- 8.3.5 Spain
- 8.3.6 Rest of Europe
8.4 Asia Pacific
- 8.4.1 Japan
- 8.4.2 China
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 New Zealand
- 8.4.6 South Korea
- 8.4.7 Rest of Asia Pacific
8.5 South America
- 8.5.1 Argentina
- 8.5.2 Brazil
- 8.5.3 Chile
- 8.5.4 Rest of South America
8.6 Middle East & Africa
- 8.6.1 Saudi Arabia
- 8.6.2 UAE
- 8.6.3 Qatar
- 8.6.4 South Africa
- 8.6.5 Rest of Middle East & Africa

9 Key Developments

9.1 Agreements, Partnerships, Collaborations and Joint Ventures
9.2 Acquisitions & Mergers
9.3 New Product Launch
9.4 Expansions
9.5 Other Key Strategies

10 Company Profiling

10.1 Bio-Rad Laboratories, Inc.
10.2 F. Hoffmann-La Roche Ltd.
10.3 Thermo Fisher Scientific, Inc.
10.4 Binx Health, Inc.
10.5 Abbott Laboratories
10.6 Hologic Inc.
10.7 Siemens Healthineers AG
10.8 ELITech Group SAS
10.9 Danaher Corporation
10.10 Seegene, Inc.
10.11 Genetic Signatures Ltd.
10.12 Becton, Dickinson and Company (BD)
10.13 Qiagen N.V.
10.14 Meridian Bioscience Inc.
10.15 PerkinElmer Inc.

CT/NG検査市場の2032年までの予測：製品別、検査タイプ別、エンドユーザー別、地域別の世界分析

CT/NG Testing Market Forecasts to 2032 - Global Analysis By Product (Assays & Kits and Instruments/Analyzers), Testing Type (Laboratory Testing and Point-of-care (POC) Testing), End User and By Geography

COVID-19の影響：

最大のシェアを占める地域：

CAGRが最も高い地域：

無料のカスタマイズサービス

本レポートをご購読のお客様には、以下の無料カスタマイズオプションのいずれかをご利用いただけます：

目次

第1章 エグゼクティブサマリー

第2章 序文

第3章 市場動向分析

第4章 ポーターのファイブフォース分析

第5章 世界のCT/NG検査市場：製品別

第6章 世界のCT/NG検査市場：検査タイプ別

第7章 世界のCT/NG検査市場：エンドユーザー別

第8章 世界のCT/NG検査市場：地域別

第9章 主な発展

第10章 企業プロファイリング